PHAXIAM Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de PHAXIAM Therapeutics disminuyan a un ritmo anual de 3.5%, mientras que sus ingresos anuales crecerán a un ritmo de 92.4% por año. Se espera que el BPA disminuya en un 1.8% al año.

Información clave

-3.5%

Tasa de crecimiento de los beneficios

-1.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	42.7%
Tasa de crecimiento de los ingresos	92.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	14 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:2E40 - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	13	-19	-39	N/A	2
12/31/2025	2	-32	-33	N/A	2
12/31/2024	1	-25	-29	N/A	2
6/30/2024	2	-22	N/A	N/A	N/A
3/31/2024	2	-23	N/A	N/A	N/A
12/31/2023	1	-23	-25	-24	N/A
9/30/2023	6	-12	N/A	N/A	N/A
6/30/2023	6	-11	-23	-23	N/A
3/31/2023	6	6	N/A	N/A	N/A
12/31/2022	7	0	-32	-32	N/A
9/30/2022	2	-18	N/A	N/A	N/A
6/30/2022	3	-27	-45	-45	N/A
3/31/2022	3	-54	N/A	N/A	N/A
12/31/2021	4	-54	-57	-57	N/A
9/30/2021	4	-61	N/A	N/A	N/A
6/30/2021	4	-66	-55	-55	N/A
3/31/2021	4	-68	N/A	N/A	N/A
12/31/2020	4	-73	-53	-52	N/A
9/30/2020	4	-73	N/A	N/A	N/A
6/30/2020	4	-68	-52	-49	N/A
3/31/2020	5	-69	N/A	N/A	N/A
12/31/2019	5	-63	-63	-43	N/A
9/30/2019	6	-52	-69	-38	N/A
6/30/2019	5	-49	-73	-52	N/A
3/31/2019	4	-38	N/A	N/A	N/A
12/31/2018	4	-38	-53	-48	N/A
9/30/2018	3	-42	N/A	N/A	N/A
6/30/2018	4	-38	-33	-31	N/A
3/31/2018	3	-39	N/A	N/A	N/A
12/31/2017	3	-34	N/A	-25	N/A
9/30/2017	4	-27	N/A	N/A	N/A
6/30/2017	4	-26	N/A	-23	N/A
3/31/2017	5	-24	N/A	N/A	N/A
12/31/2016	4	-22	N/A	-18	N/A
9/30/2016	4	-20	N/A	-17	N/A
6/30/2016	4	-19	N/A	-17	N/A
3/31/2016	3	-16	N/A	N/A	N/A
12/31/2015	3	-15	N/A	-15	N/A
9/30/2015	3	-14	N/A	-12	N/A
6/30/2015	2	-12	N/A	-10	N/A
3/31/2015	2	-11	N/A	-9	N/A
12/31/2014	2	-9	N/A	-7	N/A
9/30/2014	2	-8	N/A	-7	N/A
6/30/2014	2	-7	N/A	-6	N/A
3/31/2014	2	-8	N/A	-6	N/A
12/31/2013	2	-8	N/A	-6	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 2E40 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 2E40 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 2E40 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (92.4% al año) de 2E40 crezcan más rápidamente que los del mercado German (5.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (92.4% al año) de 2E40 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 2E40 se prevé que sea elevada dentro de 3 años.

PHAXIAM Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.90

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.81

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €7.70

New 90-day high: €6.33

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

New 90-day low: €4.30

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

New 90-day low: €4.82

New 90-day low - €6.02

New 90-day low - €6.62

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento